caseism

Organizing for Innovation at Glenmark (B) Case Solution & Answer

The case traces the journey of an Indian pharmaceutical company, Glenmark Pharmaceuticals, which has always focused on generic drugs in the field of discovery research. After India entered the global product of the patent system with the signing of the TRIPS Agreement of the WTO in 1994, a number of Indian companies tried to do discovery research. Glenmark has invested heavily in developing its capacity to conduct pharmaceutical research at high risk, and in three years has developed several promising molecules. The company has signed licensing agreements with international companies molecules two agreements with the U.S. company Eli Lilly and Company and Merck KGaA each with Forest Laboratories based in Germany and USA.’s Case brings students in 2008, one of the most critical periods in the evolution of society. Three of the four development projects Glenmark drugs have failed and the fourth is showing signs of failure. The stock price plummeted and the company management is under pressure from financial analysts to present research discovery and focus on what they had always done best generic. The event offers participants armchair CEO Glenn Saldanha Glenmark, which must, amid the pressure limitations of building and resources in the business, develop an action plan for future R & D. or may not be the business innovation? That’s the question before Saldanha, and class.
by
Nita Sachan,
Charles Dhanaraj
Source: Indian School of Business
5 pages.
Release Date: June 30, 2013. Prod #: ISB029-PDF-ENG
Organizing for innovation Glenmark Case (B) Solution

Share This

LOOK FOR A FREE CASE STUDY SOLUTION

JUST REGISTER NOW AND GET 50% OFF ON EACH CASE STUDY